Principal Financial Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-395,044
| Closed | -$4.42M | – | 2319 |
|
|
2017
Q3 | $4.42M | Sell |
395,044
-8,670
| -2% | -$95.6K | ﹤0.01% | 1591 |
|
|
2017
Q2 | $4.44M | Buy |
403,714
+1,214
| +0.3% | +$12.1K | ﹤0.01% | 1587 |
|
|
2017
Q1 | $3.94M | Buy |
402,500
+16,842
| +4% | +$168K | ﹤0.01% | 1603 |
|
|
2016
Q4 | $4.17M | Buy |
385,658
+22,484
| +6% | +$225K | 0.01% | 1574 |
|
|
2016
Q3 | $3.72M | Buy |
363,174
+11,972
| +3% | +$130K | ﹤0.01% | 1559 |
|
|
2016
Q2 | $4.59M | Buy |
+351,202
| New | +$4.6M | 0.01% | 1459 |
|
|
2015
Q3 | – | Sell |
-13,635
| Closed | -$134K | – | 2248 |
|
|
2015
Q2 | $134K | Sell |
13,635
-949
| -7% | -$8.64K | ﹤0.01% | 2103 |
|
|
2015
Q1 | $129K | Buy |
14,584
+446
| +3% | +$3.55K | ﹤0.01% | 2078 |
|
|
2014
Q4 | $124K | Sell |
14,138
-4,393
| -24% | -$35.6K | ﹤0.01% | 2094 |
|
|
2014
Q3 | $128K | Hold |
18,531
| – | – | ﹤0.01% | 2111 |
|
|
2014
Q2 | $97K | Sell |
18,531
-6,635
| -26% | -$32.3K | ﹤0.01% | 2205 |
|
|
2014
Q1 | $115K | Sell |
25,166
-306
| -1% | -$1.48K | ﹤0.01% | 2220 |
|
|
2013
Q4 | $128K | Sell |
25,472
-114
| -0.4% | -$549 | ﹤0.01% | 2226 |
|
|
2013
Q3 | $130K | Sell |
25,586
-1,667
| -6% | -$9.28K | ﹤0.01% | 2195 |
|
|
2013
Q2 | $135K | Buy |
+27,253
| New | +$130K | ﹤0.01% | 2170 |
|
Principal Financial Group's SCLN Position: Q4 2017 in Review
Principal Financial Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 395,044 shares — an estimated $4.42M sold.
Principal Financial Group first reported a position in SCLN in Q2 2013 and held it in 15 quarters. The position peaked at $4.59M in Q2 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Principal Financial Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Principal Financial Group sold 395,044 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $4.42M.
- Principal Financial Group first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Principal Financial Group's Sciclone Pharmaceuticals Inc position peaked at $4.59M in Q2 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Principal Financial Group's 13F filing for Q4 2017, filed 13 Feb 2018.